Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST6GAL1 | P15907 | 3/20 | 1.00 |
| ▸ | ST3GAL1 | Q11201 | 2/20 | 1.00 |
| ▸ | ST3GAL3 | Q11203 | 2/20 | 1.00 |
| ▸ | FUT6 | P51993 | 1/20 | 1.00 |
| ▸ | FUT5 | Q11128 | 1/20 | 1.00 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | OSBP | P22059 | 3/20 | 0.32 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15978374 | 0.86 | ST6GAL1 (0.76) | ST6GAL1ST3GAL1ST3GAL3FUT6FUT5 | |
| SCHEMBL30416028 | 0.79 | ST6GAL1 (0.73) | ST6GAL1ST3GAL1ST3GAL3FUT6FUT5 | |
| SCHEMBL29351854 | 0.75 | ST6GAL1 (0.61) | ST6GAL1ST3GAL1ST3GAL3FUT6FUT5 | |
| SCHEMBL30753545 | 0.73 | ST6GAL1 (0.66) | ST6GAL1ST3GAL1ST3GAL3FUT6FUT5 | |
| SCHEMBL8324407 | 0.70 | ST6GAL1 (0.61) | ST6GAL1ST3GAL1ST3GAL3FUT6FUT5 | |
| SCHEMBL16406505 | 0.68 | ST6GAL1 (0.51) | ST6GAL1ST3GAL1ST3GAL3FUT6FUT5 | |
| SCHEMBL29406636 | 0.68 | ST6GAL1 (0.60) | ST6GAL1ST3GAL1ST3GAL3FUT6FUT5 | |
| SCHEMBL29711314 | 0.67 | ST6GAL1 (0.56) | ST6GAL1ST3GAL1ST3GAL3FUT6FUT5 | |
| SCHEMBL30789025 | 0.62 | ST6GAL1 (0.56) | ST6GAL1ST3GAL1ST3GAL3FUT6FUT5 | |
| SCHEMBL8147735 | 0.60 | ST6GAL1 (0.46) | ST6GAL1ST3GAL1ST3GAL3FUT6FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | ST6GAL1 1006/4885ST3GAL1 799/4885ST3GAL3 1051/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ST6GAL1 375/4885ST3GAL1 1232/4885ST3GAL3 875/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | ST6GAL1 1006/4885ST3GAL1 799/4885ST3GAL3 1051/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | ST6GAL1 375/4885ST3GAL1 1232/4885ST3GAL3 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.